Overview
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.
Eligibility
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Life expectancy of at least 12 weeks.
- Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.
- Measurable disease.
Exclusion Criteria:
- Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment.
- Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment.
- Prior allogeneic SCT.
- Prior solid organ transplantation.
